Recent News

Is the COVID-19 mRNA Vaccine Effective in Patients With Multiple Myeloma?

Long-Term Findings With Chemotherapy for Newly Diagnosed Myeloma in Low-Income Setting

COVID-19 and Multiple Myeloma: Patient Questionnaire Findings From the UK

Salvage Autologous HSCT for Relapsed Myeloma: From the Polish Myeloma Study Group

SOHO 2021: Preclinical Look at Myeloma Cell Viability With Metformin Plus Lenalidomide

SOHO 2021: Does Prolonged Lenalidomide Maintenance Improve Survival After Transplant in Myeloma?

SOHO 2021: Update on BCMA-Directed CAR T-Cell Therapy for Resistant Myeloma

SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma

SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma

DREAMM-2: Sustained Activity Reported With Belantamab Mafodotin-blmf in Resistant Myeloma

Bone-Directed Therapy in Myeloma: How Often Should Bisphosphonates Be Given?

COVID-19 and Novel Agents for Myeloma: From a Single Center in the Czech Republic

Relapse-Associated Genetic Alterations and Drug-Specific Resistance in Myeloma

FDA Brief: Orphan Drug Designation for Two Novel Multiple Myeloma Treatments

COVID-19 Vaccine Responses Among Patients With Multiple Myeloma

Initial Results From Cohort A of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Myeloma

ICARIA-MM: Updated Results With Isatuximab-Based Therapy for Resistant Myeloma

BOSTON Trial: Survival Outcomes With Selinexor in Elderly Patients With Multiple Myeloma

Trends in Multiple Myeloma–Related Inpatient Mortality

Can an MRD-Adaptive Study Design Help to De-escalate Therapy for Multiple Myeloma?

Comparing Two Oral Doublet Regimens for Resistant Multiple Myeloma

FDA Issues Safety Alert for Use of Melphalan Flufenamide in Multiple Myeloma

Subcutaneous Use of BCMA-CD3 Bispecific Monoclonal Antibody in Myeloma

Adding Daratumumab to Combination Therapy for Newly Diagnosed Multiple Myeloma

First-in-Human Trial of Bispecific IgG4 Antibody for Multiple Myeloma

FDA Approves Daratumumab and Hyaluronidase-fihj Combination Therapy for Multiple Myeloma

ASCT With Carfilzomib-Based Regimens in Newly Diagnosed Multiple Myeloma

EHA2021: ANDROMEDA Trial Update Supports Daratumumab-Based Therapy for AL Amyloidosis

ASCO2021: CARTITUDE-1 Update on Ciltacabtagene Autoleucel for Resistant Myeloma

EHA2021: MRD Negativity as Myeloma Treatment Endpoint for Maintenance Therapy

ASCO 2021: Early Trial Update of Teclistamab in Resistant Multiple Myeloma

FDA Brief: Teclistamab Receives Breakthrough Therapy Designation for Resistant Myeloma

EHA2021: Targeting BCMA in Early-Phase Study in Resistant Myeloma

ASCO 2021: Durvalumab-Based Therapy for Ultra-High–Risk Newly Diagnosed Myeloma

ASCO 2021: KarMMa Update of BCMA-Directed CAR T-Cell Therapy for Refractory Myeloma

EHA2021: Iberdomide-Based Regimens for Relapsed or Refractory Multiple Myeloma

EHA2021: MAIA Trial Update on Daratumumab-Based Therapy for Newly Diagnosed Myeloma

ASCO 2021: Interim Analysis of CASSIOPEIA Trial of Daratumumab Maintenance in Myeloma

ASCO 2021: Ixazomib Maintenance After HCT in High-Risk Multiple Myeloma

Final Evidence Report From ICER on Three Therapies Targeting BCMA for Myeloma

BCMA CAR T-Cell Therapy Granted Priority Review for Multiple Myeloma

Ixazomib, Lenalidomide, and Dexamethasone in Myeloma: Routine Clinical Practice Versus Clinical Trials

Selinexor-Based Triplet in Myeloma: Impact of Age and Frailty in BOSTON Trial

Combination of Novel Antimyeloma Prototype and Cyclopamine Under Study

Does the First COVID-19 Vaccine Dose Offer Protection for Patients With Multiple Myeloma?

Peritransplant Orthostatic Hypotension and Multiple Myeloma

Frailty-Guided Treatment Strategy for Newly Diagnosed Patients With Myeloma

Risk Factors for Bloodstream Infections and Early Mortality in Multiple Myeloma

Whole-Genome Sequencing May Offer Insights to Multiple Myeloma Precursor Conditions

AACR 2021: Synergistic Selinexor-Based Combinations and Companion Biomarkers in Myeloma

Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy

AACR 2021: Role of ROBO1 Receptor in Growth of Multiple Myeloma

Weekly Carfilzomib-Based Regimen in Resistant Myeloma: Phase II Trial

Novel Oral PIM Kinase Inhibitor Under Study in Resistant Multiple Myeloma